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A B S T R A C T
Aspirin’s efﬁcacy for the prevention of secondary vascular disease is well supported. However, more
attention should be given to its side effects, especially gastrointestinal injury. A 62-year-old man
suffered acute myocardial infarction of the left main trunk. Although a percutaneous coronary
intervention, using a bare metal stent, was successful, intractable in-bowel bleeding developed. To
control the bleeding, we discontinued dual antiplatelet therapy during the acute phase, and used intra-
aortic balloon pumping to provide sufﬁcient coronary ﬂow to prevent stent thrombosis. This strategy
controlled intestinal bleeding without any thrombotic complications, indicating that intra-aortic balloon
pumping is effective for preventing stent thrombosis.
<Learning objective: Aspirin often causes bleeding complications, especially in the gastrointestinal
tract. We experienced a case with severe intestinal bleeding of unknown origin during the acute phase
after percutaneous coronary intervention for acute myocardial infarction. The dual antiplatelet therapy
was necessarily stopped, which could have resulted in stent thrombosis. We used intra-aortic balloon
pumping to prevent the stent thrombosis through coronary ﬂow augmentation.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Over the past 20–30 years, reperfusion therapy has reduced
mortalities associated with ST-segment elevation myocardial
infarctions (STEMIs). According to the current antiplatelet therapy
for Japanese patients with ST elevation acute myocardial infarction
(J-AMI) registry, percutaneous coronary intervention (PCI) was
performed for 97.2% of all STEMI patients, with an in-hospital
cardiac mortality rate of 3.2% [1]. Although the in-hospital
prognosis for STEMI patients has improved, major bleeding has
been reported as an independent risk factor for mortality after
acute myocardial infarctions (AMIs) [2]. The J-AMI prospective
multicenter registry indicated that the incidence of bleeding was
1.58%, with gastrointestinal bleeding accounting for about 30% of
all bleeding complications. Globally, antiplatelet therapy is used in* Corresponding author at: Department of Cardiology, Seirei Hamamatsu General
Hospital, 2-12-12 Sumiyoshi, Naka-ku, Hamamatsu City, Shizuoka 430-8558, Japan.
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1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightsthe primary PCI setting for treating patients with AMI, and has
been shown to reduce adverse cardiac events and prevent short-
and long-term stent thrombosis after PCI. However, antiplatelet
therapy also increases the risk of post-PCI bleeding complications.
Here, we report a patient with intestinal bleeding during the
acute phase of myocardial infarction of the left main trunk.
Discontinuation of dual antiplatelet therapy (DAPT) was required
to stop the bleeding. If stent thrombosis occurred, a fatal prognosis
was expected; therefore, we used intra-aortic balloon pumping
(IABP) to augment coronary ﬂow, anticipating that the ﬂow would
be sufﬁcient to prevent thrombosis.
Case report
A 62-year-old man with dyslipidemia, complaining of chest
compression, was admitted to the emergency department. In the
emergency room, he had a heart rate of 75 bpm and a blood
pressure of 64/38 mmHg. An electrocardiogram demonstrated ST-
segment elevation in the I, aVL, aVR, and V1–3 leads, with a wide
QRS complex (Fig. 1). A chest radiograph showed a large
cardiothoracic ratio and a butterﬂy shadow; a transthoracic reserved.
Fig. 1.
Initial patient electrocardiogram showing ST-segment elevation in the
I, aVL, aVR, and V1–3 leads; ST-segment depression in the II, III, and aVF
leads as a reciprocal change; and a wide QRS pattern.
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ejection fraction; his troponin T rapid assay was also positive.
These data led to an anterior STEMI diagnosis. After obtaining
informed consent from the patient and his family, coronary
angiography was performed; IABP and percutaneous cardiopul-
monary support was also provided. The angiogram revealed
numerous ﬂoating thrombi in his left main trunk and proximal left
anterior descending artery (Fig. 2a). We aspirated the thrombi,
directly, using a 7-Fr guiding catheter. A subsequent check, using
an intravascular ultrasound imaging system (Atlantis Pro, Boston
Scientiﬁc, Marlborough, MA, USA), revealed the presence of
numerous thrombi and atherosclerotic vulnerable plaques. A bare
metal stent (BMS; Liberte, 4.0 mm  20 mm, Boston Scientiﬁc) wasFig. 2.
Initial patient coronary angiography. (a) Pre-percutaneous coronary intervent
proximal left anterior descending artery, the line indicates the stent.implanted in the patient’s left anterior descending artery, from his
left main trunk (Fig. 2b). This procedure improved his Thromboly-
sis in Myocardial Infarction (TIMI) grade from I to II. On the same
day, he also began DAPT, involving aspirin (100 mg) and
clopidogrel (75 mg), with appropriate loading doses. The patient’s
postoperative peak creatinine kinase level was 14,668 IU/L, and his
creatinine kinase-MB isozyme concentration was 635 IU/L.
Five days postoperatively, he was weaned from the mechanical
support and heparin. Signiﬁcant melena occurred 7 days after
weaning from the mechanical device (postadmission day 12),
despite beginning the use of a proton pump inhibitor upon
admission (intravenous lansoprazole, 30 mg/day). However, upper
and lower gastrointestinal tract endoscopies could not identify the
source of the bleeding. Thus, we speculated his melena to be the
result of small bowel bleeding. The patient remained hemody-
namically unstable despite red cell concentrate transfusions and
conservative therapy; therefore, the DAPT was discontinued
22 days after admission. At this time, we re-inserted an IABP,
anticipating that the coronary ﬂow augmentation would prevent
stent thrombosis. After beginning this course of therapy, the
patient’s gastrointestinal bleeding gradually decreased, complete-
ly disappearing 6 days after stopping DAPT (postadmission day 28).
During the IABP therapy, we controlled the heparin dose to
maintain an appropriate activated partial thromboplastin time
(1.5–2.5 the normal value). The patient was weaned from the
artiﬁcial respirator on day 34, and IABP was discontinued on day
38. Clopidogrel administration alone was re-started after switch-
ing from IABP due to the potential for mucosal injury caused by the
aspirin, without melena recurrence (Fig. 3). A 4-month follow-up
coronary angiography demonstrated the absence of stent resteno-
sis, and the patient was discharged.
Discussion
This case shows three important ﬁndings. The ﬁrst is the
efﬁcacy of using IABP to prevent stent thrombosis during the acute
phase of PCI, when discontinuation of antiplatelet therapy is
necessary. The second is the consideration of both the positive and
negative aspects of aspirin. The third is that BMSs are excellent
choices for bleeding control, indicating the need to revise the
indication for the use of BMSs.
The risk factors for stent thrombosis include procedural
complications, such as coronary dissection and coronary ﬂowion (PCI). (b) Post-PCI. The arrows show thrombi ﬂoating in the left main trunk and
Fig. 3.
The patient’s clinical course. IABP, intra-aortic balloon pumping; PCPS,
percutaneous cardiopulmonary support system; RCC, red cell
concentrate; Hb, hemoglobin.
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increases coronary blood ﬂow and velocity during diastole
[3,4]. Takeuchi et al. reported that the time-averaged peak diastolic
velocity, with a non-augmented beat, was 19.2  10.5 cm/s, and that
IABP signiﬁcantly increased the time-averaged peak diastolic velocity
to 30.0  15.9 cm/s (a 61  38% increase, p < 0.001) [5]. This coronary
ﬂow is effective for reducing the risk of stent thrombosis. However,
previous reports have not described the use of IABP in conjunction with
discontinuation of DAPT.
We also discussed the suitability of ‘‘clopidogrel and heparin’’
as a replacement for ‘‘IABP and heparin.’’ Thienopyridines (e.g.
clopidogrel) are less harmful to the gastric mucosa than aspirin,
but some have reported that 22.2% of thienopyridine users have
experienced mucosal injury [6]. In the present case, controlling the
presumed intestinal bleeding as soon as possible was so critical
that we stopped administration of both antiplatelet agents. The
patient’s grade II TIMI, after PCI, led us to consider that mechanical
coronary ﬂow support, using IABP, was reasonable for preventing
stent thrombosis. Moreover, we maintained an appropriate
activated partial thromboplastin time (1.5–2.5 the normal value)
to minimize the risk of thrombosis.
The use of DAPT therapy, especially aspirin, may lead to
intractable gastrointestinal bleeding. Unfortunately, this is not a
rare complication among patients taking aspirin because aspirin
inhibits cyclooxygenase-1 and reduces the secretion of prosta-
glandin. Endo et al. reported that capsule endoscopy showed a high
rate (80%) of small bowel dysfunction among healthy volunteers
following transient administration of aspirin [7]. Nonsteroidal
anti-inﬂammatory drugs, including aspirin, induce mucosal injury
that results in intestinal bleeding more frequently than is
commonly believed.
Major bleeding during hospitalization is an independent
predictor of mortality [2]; therefore, the prevention of bleeding
has become as important as the prevention of further ischemic
events. Today, many AMI patients receive implanted drug-
eluting stents (DESs). A recent meta-analysis indicated that the
incidence of stent thrombosis in patients with acute coronary
syndrome and implanted BMSs was 4.3%, whereas patients with
DESs had a 5.8% incidence [8]. One report suggested that
everolimus-eluting stents were superior to BMSs for reducing
the incidence of stent thrombosis in patients with acute
coronary syndrome [9]. However, 90% of the subjects in thatstudy received DAPT for more than 1 year. Additionally, some
patients experienced difﬁculty in continuing DAPT, such as our
patient. We selected a BMS because it is covered with neo-
intima earlier than is a DES, which is important in patients with
unknown concomitant disease who need to stop antiplatelet
therapy due to acute bleeding complications. In the present
patient, chronic re-stenosis was also not a critical factor. We
have to reconsider the routine implantation of DESs in patients
with an unclear medical history, especially acute coronary
syndrome, as BMSs are superior in patients receiving short
courses of DAPT.
Re-endothelialization might occur at the IABP site 22 days after
BMS implantation. However, some reports have said that 20% of
patients with implanted BMSs exhibit less than 85% endothelium
stent coverage by the 6-month follow-up [10]. The present patient
had a severely high risk of stent thrombosis because of his low
ejection fraction and post-PCI TIMI grade. Stent thrombosis in the
left main trunk leads to sudden death. Therefore, stent thrombosis
requires careful consideration, especially during the early phase
after PCI, necessitating combined IABP support.
This report is the ﬁrst to describe the control of intestinal
bleeding using IABP support following DAPT discontinuation. The
use of IABP support and cessation of DAPT is of an intermediate
invasiveness. This treatment can be helpful for patients suffering
from bleeding complications during the early post-PCI period.
Conclusion
This case demonstrated that discontinuation of DAPT is an
effective means for controlling intestinal bleeding, but the
possibility of stent thrombosis provides a treatment dilemma.
Coronary ﬂow back up using IABP can be helpful in such cases; the
use of a BMS also needs to be considered.
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